Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
作者信息
Strati Paolo, Keating Michael J, Burger Jan A, O'Brien Susan M, Wierda William G, Estrov Zeev, Zacharian Gracy, Ferrajoli Alessandra
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
出版信息
Haematologica. 2017 Dec;102(12):e494-e496. doi: 10.3324/haematol.2017.171561. Epub 2017 Aug 10.
Abstract
摘要
相似文献
1
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.来那度胺在慢性淋巴细胞白血病一线或挽救性化疗免疫治疗后的巩固治疗
Haematologica. 2017 Dec;102(12):e494-e496. doi: 10.3324/haematol.2017.171561. Epub 2017 Aug 10.
2
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).在未经治疗的慢性淋巴细胞白血病（CLL）中，化疗免疫治疗后进行来那度胺巩固治疗的 II 期试验中，T 细胞突触活性的长期修复。
Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14.
3
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.来那度胺用于高危慢性淋巴细胞白血病一线治疗后的维持治疗（CLLM1）：一项随机、双盲、3期研究的最终结果
Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12.
4
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.来那度胺停药后慢性淋巴细胞白血病患者的持续长期反应。
Leukemia. 2018 Oct;32(10):2278-2281. doi: 10.1038/s41375-018-0059-3. Epub 2018 Feb 20.
5
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.苯达莫司汀+利妥昔单抗化学免疫疗法及来那度胺维持治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：威斯康星肿瘤学网络研究
Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.
6
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.来那度胺维持治疗既往接受过治疗的慢性淋巴细胞白血病（CONTINUUM）：一项随机、双盲、安慰剂对照的3期试验。
Lancet Haematol. 2017 Nov;4(11):e534-e543. doi: 10.1016/S2352-3026(17)30168-0. Epub 2017 Sep 25.
7
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.来那度胺治疗慢性淋巴细胞白血病患者时发生的B细胞急性淋巴细胞白血病
Blood. 2021 Apr 22;137(16):2267-2271. doi: 10.1182/blood.2020008609.
8
Jump-starting the T cells in CLL.启动 CLL 中的 T 细胞。
Blood. 2013 May 16;121(20):4016-7. doi: 10.1182/blood-2013-04-491787.
9
High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.高剂量疗法及自体造血细胞移植作为慢性淋巴细胞白血病一线巩固治疗：一项系统综述
Bone Marrow Transplant. 2015 Aug;50(8):1069-74. doi: 10.1038/bmt.2015.69. Epub 2015 Apr 13.
10
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.性别对慢性淋巴细胞白血病患者化疗免疫治疗后结局的影响：德国慢性淋巴细胞白血病研究组的一项荟萃分析
Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12.
引用本文的文献
1
Maintenance therapy for chronic lymphocytic leukaemia.慢性淋巴细胞白血病的维持治疗。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD013474. doi: 10.1002/14651858.CD013474.pub2.
2
A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.网络荟萃分析在慢性淋巴细胞白血病中的维持治疗。
PLoS One. 2020 Jan 29;15(1):e0226879. doi: 10.1371/journal.pone.0226879. eCollection 2020.
3
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.一线氟达拉滨、环磷酰胺和利妥昔单抗治疗后 CD4 T 细胞耗竭对慢性淋巴细胞白血病的预后作用。
BMC Cancer. 2019 Aug 14;19(1):809. doi: 10.1186/s12885-019-5971-z.
4
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.来那度胺和利妥昔单抗治疗初治和复发 CLL 患者的疗效和反应预测因素。
Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.
本文引用的文献
1
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.苯达莫司汀+利妥昔单抗化学免疫疗法及来那度胺维持治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：威斯康星肿瘤学网络研究
Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.
2
Targeted therapies for CLL: Practical issues with the changing treatment paradigm.慢性淋巴细胞白血病的靶向治疗：治疗模式转变带来的实际问题
Blood Rev. 2016 May;30(3):233-44. doi: 10.1016/j.blre.2015.12.002. Epub 2015 Dec 24.
3
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.来那度胺可诱导老年慢性淋巴细胞白血病患者产生持久缓解。
Blood. 2013 Aug 1;122(5):734-7. doi: 10.1182/blood-2013-04-495341. Epub 2013 Jun 25.
4
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).在未经治疗的慢性淋巴细胞白血病（CLL）中，化疗免疫治疗后进行来那度胺巩固治疗的 II 期试验中，T 细胞突触活性的长期修复。
Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14.
Zotero 插件